OFFICIAL PUBLICATION OF

by its subsidiary APPco

April MIMS update

Guest Author 11/04/2024

We look at some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products Fezolinetant (Veoza) is a nonhormonal selective NK3 receptor antagonist that blocks neurokinin B (NKB) binding on kisspeptin/neurokinin B/dynorphin (KNDy) neurons to modulate neuronal activity in the thermoregulatory centre. The thermoregulatory centre in the hypothalamus is

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

‘I can feel the walls closing in on me as this snowballs’

I would argue quality varies in any profession. Most GPs will not refer to a provider where the quality is…

Big Pharma

Wesfarmers targets affordable healthcare

When healthcare is treated as a commodity and patients regarded as consumers, health outcomes are compromised and overall healthcare spending…

Edward Hatfield

April MIMS update

Previous Locum rates forecast to flatten

Next Are pharmacists ready for a rebound in Chinese customers?

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous Locum rates forecast to flatten

Next Are pharmacists ready for a rebound in Chinese customers?

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.